

What is claimed is:

1. A method for selectively inhibiting T-cell rolling in a human host, comprising administering a compound that selectively interferes with the CLA-E selectin interaction and LFA-1/ICAM and VLA/VACM interactions.
2. The method of claim 1 wherein said compound is an immunostimulant.
3. The method of claim 1 wherein said compound includes an immunotherapeutic agent, said agent comprising a purified protein extract wherein said purified extract is isolated by diethylaminoethyl Sephadex chromatography of a Nonidet P-40 insoluble particulate antigen fraction derived from isolated killed cells of amastigotes from at least one species of the *Leishmania* genus, said particulate antigen fraction solubilized with 8 M urea and 0.025 M. Tris[hydroxymethyl]aminomethane pH 8.3 applied to diethylaminoethyl Sephadex and eluted with a solution comprising 0.1 M. sodium chloride, 8 M urea and 0.025 M. Tris[hydroxymethyl]aminomethane pH 8.3, said purified protein extract including polypeptides having apparent molecular weights after total reduction and alkylation of 73, 80 and 82 kDa.
  4. The method of claim 3 wherein the species is *Leishmania amazonensis*.
  5. The method of claim 3, wherein the species is *Leishmania venezuelensis*.
  6. The method of claim 3, wherein the species is *Leishmania brasiliensis*.
  7. The method of claim 3, wherein the species is *Leishmania chagasi*.
  8. The method of claim 3, wherein the species are *Leishmania amazonensis*, *Leishmania venezuelensis*, *Leishmania brasiliensis* and *Leishmania chagasi*.
  9. The method of claim 3, wherein the 73 kDa polypeptide comprises the amino acid sequences set forth in SEQ ID NOS: 1, 5 and 6, wherein the 80 kDa polypeptide comprises the amino acids sequences set forth in SEQ ID NOS: 1, 3 and 4 and wherein the 82 kDa polypeptide comprises the amino acids sequences set forth in SEQ ID NOS: 1 and 2.

10. The method of any one of claims 3-9 further comprising an adjuvant.
11. The method of claim 10, wherein the adjuvant is alumina.
12. The method of claim 1 wherein said compound includes an immunotherapeutic agent, said agent comprising an immunotherapeutic agent, said agent comprising a purified protein extract wherein said purified extract is isolated by diethylaminoethyl Sephadex chromatography of a Nonidet P-40 insoluble particulate antigen fraction derived from isolated killed cells of amastigotes from at least one species of the *Leishmania* genus, said particulate antigen fraction solubilized with 8 M urea and 0.025 M. Tris[hydroxymethyl]aminomethane pH 8.3 applied to diethylaminoethyl Sephadex and eluted with a solution comprising 0.15 M. sodium chloride, 8 M urea and 0.025 M. Tris[hydroxymethyl]aminomethane pH 8.3, said purified protein extract including polypeptide having apparent molecular weights after total reduction and alkylation of 73, 80 and 82 kDa.
13. The method of claim 12, wherein the species is *Leishmania amazonensis*.
14. The method of claim 12, wherein the species is *Leishmania venezuelensis*.
15. The method of claim 12, wherein the species is *Leishmania brasiliensis*.
16. The method of claim 12, wherein the species is *Leishmania chagasi*.
17. The method of claim 12, wherein the species are *Leishmania amazonensis*, *Leishmania venezuelensis*, *Leishmania brasiliensis* and *Leishmania chagasi*.
18. The method of claim 12, wherein the 73 kDa polypeptide comprises the amino acid sequences set forth in SEQ ID NOS: 12, 13 and 14, wherein the 80 kDa polypeptide comprises the amino acids sequences set forth in SEQ ID NOS: 1, 3 and 10 and wherein the 82 kDa polypeptide comprises the amino acids sequences set forth in SEQ ID NOS: 7, 8 and 9.
19. The method of any one of claims 12-18 further comprising an adjuvant.
20. The method of claim 19, wherein the adjuvant is alumina.